menu
    • menu

    Find Clorazepate Dipotassium manufacturers, exporters & distributors on PharmaCompass

    Nuray Clorazepate Dipotassium

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    ACTIVE PHARMA INGREDIENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Synopsis

    Product SearchProduct Search

    Synopsis

    ACTIVE PHARMA INGREDIENTS

    11

    API Suppliers

    API Suppliers

    7

    USDMF

    US DMFs Filed

    2

    CEP/COS

    CEP/COS Certifications

    1

    JDMF

    JDMFs Filed

    0

    EU WC

    EU WC

    0

    KDMF

    KDMF

    3

    NDC API

    NDC API

    0

    VMF

    NDC API

    5

    Listed Suppliers

    Other Suppliers

    API REF. PRICE (USD/KG)

    $
    $ 6,032

    MARKET PLACE

    2

    API

    0

    FDF

    1INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    114

    FDF Dossiers

    FDF Dossiers

    85

    FDA Orange Book

    FDA (Orange Book)

    25

    Europe

    Europe

    3

    Canada

    Canada

    0

    Australia

    Australia

    1

    South Africa

    South Africa

    0

    Listed Dossiers

    Listed Dossiers

    0 DRUGS IN DEVELOPMENT

    FDF DossiersDRUG PRODUCT COMPOSITIONS

    REF. STANDARDS OR IMPURITIES

    3

    EDQM

    1

    USP

    0

    JP

    1

    Others

    PATENTS & EXCLUSIVITIES

    0

    US Patents

    0

    US Exclusivities

    0

    Health Canada Patents

    DIGITAL CONTENT

    0

    Data Compilation #PharmaFlow

    0

    Stock Recap #PipelineProspector

    0

    Weekly News Recap #Phispers

    3

    News #PharmaBuzz

    GLOBAL SALES INFORMATION

    US Medicaid

    18,875,252

    Annual Reports

    NA

    Finished Drug Prices

    Listed Dossiers

    82 RELATED EXCIPIENT COMPANIES

    127EXCIPIENTS BY APPLICATIONS

    Chemistry

    Click the arrow to open the dropdown
    read-moreClick the button for full data set
    read-moreClick the button for full data set
    Also known as: Clorazepic acid, Chlorazepate, 23887-31-2, 7-chloro-2,3-dihydro-2,2-dihydroxy-5-phenyl-1h-1,4-benzodiazepine-3-carboxylic acid, 7-chloro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine-3-carboxylic acid, 149128-44-9
    Molecular Formula
    C16H11ClN2O3
    Molecular Weight
    314.72  g/mol
    InChI Key
    XDDJGVMJFWAHJX-UHFFFAOYSA-N
    FDA UNII
    D51WO0G0L4
    Clorazepate Dipotassium
    A water-soluble benzodiazepine derivative effective in the treatment of anxiety. It has also muscle relaxant and anticonvulsant actions.
    Clorazepic acid is a Benzodiazepine.
    1 2D Structure

    Clorazepate Dipotassium

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    7-chloro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine-3-carboxylic acid
    2.1.2 InChI
    InChI=1S/C16H11ClN2O3/c17-10-6-7-12-11(8-10)13(9-4-2-1-3-5-9)19-14(16(21)22)15(20)18-12/h1-8,14H,(H,18,20)(H,21,22)
    2.1.3 InChI Key
    XDDJGVMJFWAHJX-UHFFFAOYSA-N
    2.1.4 Canonical SMILES
    C1=CC=C(C=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)C(=O)O
    2.2 Other Identifiers
    2.2.1 UNII
    D51WO0G0L4
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. 4306-cb

    2. Chlorazepate

    3. Clorazepate Dipotassium

    4. Clorazepate Monopotassium

    5. Clorazepic Acid

    6. Dipotassium Chlorazepate

    7. Tranxene

    8. Tranxilium

    2.3.2 Depositor-Supplied Synonyms

    1. Clorazepic Acid

    2. Chlorazepate

    3. 23887-31-2

    4. 7-chloro-2,3-dihydro-2,2-dihydroxy-5-phenyl-1h-1,4-benzodiazepine-3-carboxylic Acid

    5. 7-chloro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine-3-carboxylic Acid

    6. 149128-44-9

    7. 7-chloro-2-oxo-5-phenyl-2,3-dihydro-1h-1,4-benzodiazepine-3-carboxylic Acid

    8. 1h-1,4-benzodiazepine-3-carboxylic Acid, 7-chloro-2,3-dihydro-2-oxo-5-phenyl-

    9. 4306-cb Free Acid

    10. Chebi:3761

    11. D51wo0g0l4

    12. Abbott-35616 Free Acid

    13. Cchlorazepic Acid

    14. Clorazepic Acid [ban]

    15. Dea No. 2768

    16. 7-chloro-2,3-dihydro-2-oxo-5-phenyl-1h-1,4-benzodiazepine-3-carboxylic Acid

    17. Hsdb 3041

    18. 4306 Cb

    19. Einecs 245-926-8

    20. Unii-d51wo0g0l4

    21. Tranxene®

    22. (chloromethyl)(dimethyl)(tridecyloxy)silane

    23. Clorazepate [vandf]

    24. Clorazepic Acid [mi]

    25. Clorazepic Acid [hsdb]

    26. Gtpl7548

    27. Schembl1649064

    28. Chembl1213252

    29. Clorazepic Acid [mart.]

    30. Schembl21244066

    31. Clorazepic Acid [who-dd]

    32. Dtxsid20863674

    33. 23887-31-2 (free Acid)

    34. Db00628

    35. C06921

    36. Q418850

    37. 149128-42-7

    2.4 Create Date
    2005-03-25
    3 Chemical and Physical Properties
    Molecular Weight 314.72 g/mol
    Molecular Formula C16H11ClN2O3
    XLogP33.3
    Hydrogen Bond Donor Count2
    Hydrogen Bond Acceptor Count4
    Rotatable Bond Count2
    Exact Mass314.0458199 g/mol
    Monoisotopic Mass314.0458199 g/mol
    Topological Polar Surface Area78.8 Ų
    Heavy Atom Count22
    Formal Charge0
    Complexity488
    Isotope Atom Count0
    Defined Atom Stereocenter Count0
    Undefined Atom Stereocenter Count1
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1
    4 Drug and Medication Information
    4.1 Drug Information
    1 of 6  
    Drug NameClorazepate dipotassium
    PubMed HealthClorazepate (By mouth)
    Drug ClassesAntianxiety, Anticonvulsant
    Drug LabelThe compound occurs as a fine, light yellow, practically odorless powder. It is insoluble in the common organic solvents, but very soluble in water. Aqueous solutions are unstable, clear, light yellow, and alkaline.Clorazepate dipotassium tablets con...
    Active IngredientClorazepate dipotassium
    Dosage FormTablet
    RouteOral
    Strength3.75mg; 7.5mg; 15mg
    Market StatusPrescription
    CompanyRanbaxy; Taro; Mylan

    2 of 6  
    Drug NameGen-xene
    PubMed HealthClorazepate (By mouth)
    Drug ClassesAntianxiety, Anticonvulsant
    Drug LabelChemically, TRANXENE is a benzodiazepine. The empirical formula is C16H11ClK2N2O4; the molecular weight is 408.92; 1H-1, 4-Benzodiazepine-3-carboxylic acid, 7-chloro-2,3-dihydro-2-oxo-5-phenyl-, potassium salt compound with potassium hydroxide (1:1)...
    Active IngredientClorazepate dipotassium
    Dosage FormTablet
    RouteOral
    Strength7.5mg; 15mg; 3.75mg
    Market StatusPrescription
    CompanyAlra

    3 of 6  
    Drug NameTranxene
    Active IngredientClorazepate dipotassium
    Dosage FormTablet
    RouteOral
    Strength7.5mg; 15mg; 3.75mg
    Market StatusPrescription
    CompanyRecordati Rare

    4 of 6  
    Drug NameClorazepate dipotassium
    PubMed HealthClorazepate (By mouth)
    Drug ClassesAntianxiety, Anticonvulsant
    Drug LabelThe compound occurs as a fine, light yellow, practically odorless powder. It is insoluble in the common organic solvents, but very soluble in water. Aqueous solutions are unstable, clear, light yellow, and alkaline.Clorazepate dipotassium tablets con...
    Active IngredientClorazepate dipotassium
    Dosage FormTablet
    RouteOral
    Strength3.75mg; 7.5mg; 15mg
    Market StatusPrescription
    CompanyRanbaxy; Taro; Mylan

    5 of 6  
    Drug NameGen-xene
    PubMed HealthClorazepate (By mouth)
    Drug ClassesAntianxiety, Anticonvulsant
    Drug LabelChemically, TRANXENE is a benzodiazepine. The empirical formula is C16H11ClK2N2O4; the molecular weight is 408.92; 1H-1, 4-Benzodiazepine-3-carboxylic acid, 7-chloro-2,3-dihydro-2-oxo-5-phenyl-, potassium salt compound with potassium hydroxide (1:1)...
    Active IngredientClorazepate dipotassium
    Dosage FormTablet
    RouteOral
    Strength7.5mg; 15mg; 3.75mg
    Market StatusPrescription
    CompanyAlra

    6 of 6  
    Drug NameTranxene
    Active IngredientClorazepate dipotassium
    Dosage FormTablet
    RouteOral
    Strength7.5mg; 15mg; 3.75mg
    Market StatusPrescription
    CompanyRecordati Rare

    4.2 Therapeutic Uses

    FOR SYMPTOMATIC RELIEF OF ANXIETY ASSOCIATED WITH NEUROSIS, PSYCHONEUROSES WITH SYMPTOMS OF ANXIETY, & AS ADJUNCT IN DISEASE STATES IN WHICH ANXIETY IS PROMINENT FEATURE. /DIPOTASSIUM SALT/

    Osol, A. and J.E. Hoover, et al. (eds.). Remington's Pharmaceutical Sciences. 15th ed. Easton, Pennsylvania: Mack Publishing Co., 1975., p. 1010

    RESULTS SUGGEST THAT CLORAZEPATE DIPOTASSIUM WHEN ADDED TO STD REGIMEN IN LOW DOSES, IS USEFUL IN TREATMENT OF INTRACTABLE MINOR SEIZURES. /CLORAZEPATE DIPOTASSIUM/

    BOOKER HE; J AM MED ASSOC 229 (JUL): 552-5 (1974)

    RESULTS SHOWED NO DIFFERENCE BETWEEN THE TWO & RESPONSE DID NOT DIFFER ACCORDING TO TYPE OF ANXIETY--PSYCHOLOGICAL OR SOMATIC. /FROM ABSTRACT/

    PMID:23489 BURROW ET AL; MED J AUST 2 (OCT): 525-8 (1977)

    Management of alcohol withdrawal /Clorazepate dipotassium from table/

    Gilman, A.G., T.W. Rall, A.S. Nies and P. Taylor (eds.). Goodman and Gilman's The Pharmacological Basis of Therapeutics. 8th ed. New York, NY. Pergamon Press, 1990., p. 357

    For more Therapeutic Uses (Complete) data for CLORAZEPATE (8 total), please visit the HSDB record page.

    4.3 Drug Warning

    THIS DRUG SHOULD NOT BE DISCONTINUED ABRUPTLY, ALTHOUGH NO SERIOUS ADVERSE EFFECTS WERE OBSERVED UPON ABRUPT DISCONTINUATION OF 6 WK COURSE OF 120 MG DAILY. LONG-TERM THERAPY WITH LARGER THAN USUAL DOSES MAY RESULT IN PSYCHIC & PHYSICAL DEPENDENCE. /CLORAZEPATE DIPOTASSIUM SALT/

    American Medical Association, AMA Department of Drugs, AMA Drug Evaluations. 3rd ed. Littleton, Massachusetts: PSG Publishing Co., Inc., 1977., p. 414

    CLORAZEPATE POTASSIUM REQUIRES SAME WARNINGS & PRECAUTIONS REGARDING USE WITH OTHER DRUGS, USE IN HYPERSENSITIVE INDIVIDUALS, USE DURING PREGNANCY & IN YOUNG CHILDREN, USE IN ELDERLY & EXCESSIVELY DEPRESSED PATIENT ... AS WITH OTHER BENZODIAZEPINES ... . /CLORAZEPATE DIPOTASSIUM/

    Osol, A. and J.E. Hoover, et al. (eds.). Remington's Pharmaceutical Sciences. 15th ed. Easton, Pennsylvania: Mack Publishing Co., 1975., p. 1010

    CLORAZEPATE POTASSIUM REQUIRES ... PRECAUTIONS ... IN PATIENT WITH IMPAIRED RENAL OR HEPATIC FUNCTION, & USE IN PATIENT WITH HISTORY OF DRUG ADDICTION AS WITH OTHER BENZODIAZEPINES ... . /CLORAZEPATE DIPOTASSIUM/

    Osol, A. and J.E. Hoover, et al. (eds.). Remington's Pharmaceutical Sciences. 15th ed. Easton, Pennsylvania: Mack Publishing Co., 1975., p. 1010

    PATIENTS RECEIVING ANY BENZODIAZEPINE CMPD SHOULD BE WARNED TO AVOID ALCOHOL, SINCE CONCURRENT INGESTION COULD RESULT IN AN IMPAIRMENT OF THEIR ABILITY TO DRIVE AUTOMOBILE OR OPERATE HAZARDOUS MACHINERY. /BENZODIAZEPINE CMPD/

    Evaluations of Drug Interactions. 2nd ed. and supplements. Washington, DC: American Pharmaceutical Assn., 1976, 1978., p. 47

    For more Drug Warnings (Complete) data for CLORAZEPATE (10 total), please visit the HSDB record page.

    4.4 Drug Indication

    For the management of anxiety disorders or for the short-term relief of the symptoms of anxiety. Also used as adjunctive therapy in the management of partial seizures and for the symptomatic relief of acute alcohol withdrawal.

    5 Pharmacology and Biochemistry
    5.1 Pharmacology

    Clorazepate is a member of the group of drugs called benzodiazepines. Pharmacologically, clorazepate has the characteristics of the benzodiazepines. It has depressant effects on the central nervous system. The primary metabolite, nordiazepam, quickly appears in the blood stream. Studies in healthy men have shown that clorazenate has depressant effects on the central nervous system. Since orally administered clorazepate dipotassium is rapidly decarboxylated to form nordiazepam, there is essentially no circulating parent drug.

    5.2 MeSH Pharmacological Classification

    Anticonvulsants

    Drugs used to prevent SEIZURES or reduce their severity. (See all compounds classified as Anticonvulsants.)

    GABA Modulators

    Substances that do not act as agonists or antagonists but do affect the GAMMA-AMINOBUTYRIC ACID receptor-ionophore complex. GABA-A receptors (RECEPTORS, GABA-A) appear to have at least three allosteric sites at which modulators act: a site at which BENZODIAZEPINES act by increasing the opening frequency of GAMMA-AMINOBUTYRIC ACID-activated chloride channels; a site at which BARBITURATES act to prolong the duration of channel opening; and a site at which some steroids may act. GENERAL ANESTHETICS probably act at least partly by potentiating GABAergic responses, but they are not included here. (See all compounds classified as GABA Modulators.)

    Anti-Anxiety Agents

    Agents that alleviate ANXIETY, tension, and ANXIETY DISORDERS, promote sedation, and have a calming effect without affecting clarity of consciousness or neurologic conditions. ADRENERGIC BETA-ANTAGONISTS are commonly used in the symptomatic treatment of anxiety but are not included here. (See all compounds classified as Anti-Anxiety Agents.)

    5.3 FDA Pharmacological Classification
    5.3.1 Active Moiety
    CLORAZEPIC ACID
    5.3.2 FDA UNII
    D51WO0G0L4
    5.3.3 Pharmacological Classes
    Chemical Structure [CS] - Benzodiazepines
    5.4 Absorption, Distribution and Excretion

    Absorption

    Rapidly absorbed following oral administration (bioavailability is 91%).

    Route of Elimination

    The drug is metabolized in the liver and excreted primarily in the urine.

    PRIMARY METABOLITE, NORDIAZEPAM, REACHES PEAK LEVELS IN PLASMA IN 1 HR; PLASMA HALF-LIFE IS ABOUT 24 HR.

    Osol, A. and J.E. Hoover, et al. (eds.). Remington's Pharmaceutical Sciences. 15th ed. Easton, Pennsylvania: Mack Publishing Co., 1975., p. 1010

    PLASMA HALF-LIFE ELIMINATION COEF, CONCN, & APPARENT VOL OF DISTRIBUTION CALCULATED & MEAN VALUES WERE 53 HR, 0.0147 HR-1, 884 NG/ML, & 1.13 L/KG.

    POST ET AL; PSYCHOPHARMACOLOGY (BERLIN) 53 (2): 105-9 (1977)

    TIME REQUIRED TO REACH PEAK SERUM CONCN OF N-DIMETHYLDIAZEPAM, METABOLITE OF CHLORAZEPATE, WAS 80 MIN. MEAN HALF-LIFE 62 HR. DATA FOR OTHERS GIVEN.

    WRETLIND M ET AL; ACTA PHARMACOL TOXICOL, SUPPL 40 (1): 28-39 (1977)

    WHEN ADMIN IM, CLORAZEPATE WAS RAPIDLY ABSORBED & PEAK CONCN REACHED IN 2 HR. ABSORPTION HALF-LIFE WAS 0.77 HR IN PREGNANT WOMEN & 0.56 HR IN NONPREGNANT WOMEN.

    PMID:37089 REY ET AL; EUR J CLIN PHARMACOL 15 (3): 175-80 (1979)

    For more Absorption, Distribution and Excretion (Complete) data for CLORAZEPATE (12 total), please visit the HSDB record page.

    5.5 Metabolism/Metabolites

    The drug is metabolized in the liver and excreted primarily in the urine. The primary metabolite, nordiazepam, is further metabolized by hydroxylation. The major urinary metabolite is conjugated oxazepam (3-hydroxynordiazepam), and smaller amounts of conjugated p-hydroxynordiazepam and nordiazepam are also found in the urine.

    CHLORAZEPATE IS PROBABLY CONVERTED TO N-DIMETHYL DIAZEPAM, WHICH IS THEN OXIDIZED TO OXAZEPAM. /CHLORAZEPATE/

    Goodman, L.S., and A. Gilman. (eds.) The Pharmacological Basis of Therapeutics. 5th ed. New York: Macmillan Publishing Co., Inc., 1975., p. 189

    PRIMARY METABOLITE /IS/ NORDIAZEPAM ... .

    Osol, A. and J.E. Hoover, et al. (eds.). Remington's Pharmaceutical Sciences. 15th ed. Easton, Pennsylvania: Mack Publishing Co., 1975., p. 1010

    Following oral administration of clorazepate dipotassium, it appears that most of the drug is rapidly decarboxylated in the GI tract and is absorbed as desmethyldiazepam (nordiazepam). The rate of decarboxylation of clorazepate decreases as gastric pH increases. /Clorazepate dipotassium/

    McEvoy, G.K. (ed.). American Hospital Formulary Service - Drug Information 92. Bethesda, MD: American Society of Hospital Pharmacists, Inc., 1992 (Plus Supplements 1992)., p. 1331

    Clorazepate active metabolites in liver are desmethyldiazepam, and oxazepam; active substances in blood include desmethyldiazepam. /From table/

    Ellenhorn, M.J. and D.G. Barceloux. Medical Toxicology - Diagnosis and Treatment of Human Poisoning. New York, NY: Elsevier Science Publishing Co., Inc. 1988., p. 582

    For more Metabolism/Metabolites (Complete) data for CLORAZEPATE (8 total), please visit the HSDB record page.

    5.6 Biological Half-Life

    The serum half-life is about 2 days. Nordiazepam, the primary metabolite, quickly appears in the blood and is eliminated from the plasma with an apparent half-life of about 40 to 50 hours.

    PLASMA HALF-LIFE ... 53 HR ... .

    POST ET AL; PSYCHOPHARMACOLOGY (BERLIN) 53 (2): 105-9 (1977)

    PRIMARY METABOLITE, NORDIAZEPAM, ... PLASMA HALF-LIFE IS ABOUT 24 HR.

    Osol, A. and J.E. Hoover, et al. (eds.). Remington's Pharmaceutical Sciences. 15th ed. Easton, Pennsylvania: Mack Publishing Co., 1975., p. 1010

    N-DIMETHYLDIAZEPAM, METABOLITE OF CHLORAZEPATE: MEAN HALF-LIFE 62 HR.

    WRETLIND M ET AL; ACTA PHARMACOL TOXICOL, SUPPL 40 (1): 28-39 (1977)

    CLORAZEPATE ADMIN IM TO PREGNANT & NONPREGNANT WOMEN. ELIMINATION HALF-LIFE WERE 1.3 HR IN PREGNANT WOMEN & 2.0 HR IN NONPREGNANT WOMEN. ITS METABOLITE, NORDIAZEPAM, REACHED PEAK CONCN WITHIN 12 HR. HALF-LIFE OF ELIMINATION FOR METABOLITE WAS 180 IN PREGNANT & 60 HR IN NONPREGNANT WOMEN.

    PMID:37089 REY ET AL; EUR J CLIN PHARMACOL 15 (3): 175-80 (1979)

    Elimination half-lives for metabolites: desmethyldiazepam (30-200 hr) and oxazepam (3-21 hr)

    McEvoy, G.K. (ed.). American Hospital Formulary Service - Drug Information 92. Bethesda, MD: American Society of Hospital Pharmacists, Inc., 1992 (Plus Supplements 1992)., p. 1331

    5.7 Mechanism of Action

    Benzodiazepines bind nonspecifically to benzodiazepine receptors BNZ1, which mediates sleep, and BNZ2, which affects affects muscle relaxation, anticonvulsant activity, motor coordination, and memory. As benzodiazepine receptors are thought to be coupled to gamma-aminobutyric acid-A (GABAA) receptors, this enhances the effects of GABA by increasing GABA affinity for the GABA receptor. Binding of the inhibitory neurotransmitter GABA to the site opens the chloride channel, resulting in a hyperpolarized cell membrane that prevents further excitation of the cell.

    The effects of benzodiazepines on the waking EEG resemble those of other sedative-hypnotic drugs. Alpha activity is decreased, and there is an increase in low-voltage fast activity, especially beta activity. /Benzodiazepines/

    Gilman, A.G., T.W. Rall, A.S. Nies and P. Taylor (eds.). Goodman and Gilman's The Pharmacological Basis of Therapeutics. 8th ed. New York, NY. Pergamon Press, 1990., p. 349

    Acticonvulsant actions of the benzodiazepines, as well as other effects that occur at nonsedating doses, result in large part from their ability to enhance GABA-induced increases in the conductance of chloride. /Benzodiazepines/

    Gilman, A.G., T.W. Rall, A.S. Nies and P. Taylor (eds.). Goodman and Gilman's The Pharmacological Basis of Therapeutics. 8th ed. New York, NY. Pergamon Press, 1990., p. 454

    Benzodiazepines appear to produce their sedative, hypnotic, anxiolytic, and anticonvulsant actions by binding to specific pharmacologic receptors in the central nervous system. Benzodiazepine receptors are most concentrated in the cerebral cortex but are also found in the cerebellum, amygdala, hippocampus, hypothalamus, and spinal cord. Receptors have also been identified outside CNS, although peripheral receptors do not appear to have significant physiologic effects. The molecular receptor for the benzodiazepine molecule is a glycoprotein located on the lipid membranes of both neural and glial cells. It is speculated that there are at least two classes of benzodiazepine receptor believed to mediate different specific effects. Type I receptors predominate in the cerebelar cortex, and both type I and type II receptors are found in the cerebral cortex and hippocampus. Type I rceptors are postulated to mediate anxiolytic effects, and type II receptors mediate the sedative and other actions of benzodiazepines. No endogenous ligand or neurotransmitter for these receptors has been identified. /Benzodiazepines/

    Haddad, L.M., Clinical Management of Poisoning and Drug Overdose. 2nd ed. Philadelphia, PA: W.B. Saunders Co., 1990., p. 806

    API SUPPLIERS

    read-more
    read-more
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    API Reference Price

    read-more
    read-more
    [{"dataSource":"API Import","activeIngredients":"CLORAZEPATE DIPOTASSIUM","year":"2021","qtr":"Q1","strtotime":1613932200,"product":"CLORAZEPATE DIPOTASSIUM (FOR R&D PURPOSE) CBN NO.P-IMP-10036\/2021 DT.15.01.2021 VALID UPTO 15.07.2021","address":"98, GOVT.INDUSTRIAL AREA,CHARKOP, KANDIVALI(W),","city":"MUMBAI.","supplier":"CAMBREX CORPORATION","supplierCountry":"ITALY","foreign_port":"MILAN - MALPENSA","customer":"AJANTA PHARMA LIMITED","customerCountry":"INDIA","quantity":"1.00","actualQuantity":"1","unit":"KGS","unitRateFc":"6500","totalValueFC":"6579.8","currency":"USD","unitRateINR":"479050","date":"22-Feb-2021","totalValueINR":"479050","totalValueInUsd":"6579.8","indian_port":"BOMBAY AIR","hs_no":"29339100","bill_no":"2871465","productDescription":"API","marketType":"REGULATED MARKET","country":"ITALY","selfForZScoreResived":"Pharma Grade","supplierPort":"MILAN - MALPENSA","supplierAddress":"","customerAddress":"98, GOVT.INDUSTRIAL AREA,CHARKOP, KANDIVALI(W),"},{"dataSource":"API Import","activeIngredients":"","year":"2022","qtr":"Q1","strtotime":1643567400,"product":"CLORAZEPATE DIPOTASSIUM-0.02KGS(FOR R&D PURPOSE) (CBN IMP\/PNO.P-IMP-10589\/2021 DT.18.11.21 VALID UPTO 17.05.2022)","address":"AJANTA HOUSE. 98 GOVT. IND. AREA CHARKOP KANDIVALI WEST Contact No:","city":"MUMBAI","supplier":"CAMBREX CORPORATION","supplierCountry":"ITALY","foreign_port":"SEGRATE AIRPRT MILAN","customer":"AJANTA PHARMA LIMITED","customerCountry":"INDIA","quantity":"0.02","actualQuantity":"20","unit":"GMS","unitRateFc":"50","totalValueFC":"1155.8","currency":"EUR","unitRateINR":"4305","date":"31-Jan-2022","totalValueINR":"86100","totalValueInUsd":"1155.8","indian_port":"BOMBAY AIR","hs_no":"29339100","bill_no":"7303591","productDescription":"API","marketType":"REGULATED MARKET","country":"ITALY","selfForZScoreResived":"Pharma Grade","supplierPort":"SEGRATE AIRPRT MILAN","supplierAddress":"","customerAddress":"AJANTA HOUSE. 98 GOVT. IND. AREA CHARKOP KANDIVALI WEST Contact No:"},{"dataSource":"API Import","activeIngredients":"","year":"2022","qtr":"Q1","strtotime":1643999400,"product":"CLORAZEPATE DIPOTASSIUM","address":"304,ATLANTA ARCADE, MAROL CHURCH RD,ANDHERI EAST Contac","city":"MUMBAI","supplier":"CAMBREX CORPORATION","supplierCountry":"ITALY","foreign_port":"NA","customer":"MACLEODS PHARMACEUTICALS LTD","customerCountry":"INDIA","quantity":"0.56","actualQuantity":"0.56","unit":"KGS","unitRateFc":"6500","totalValueFC":"4186","currency":"EUR","unitRateINR":"560300","date":"05-Feb-2022","totalValueINR":"313768","totalValueInUsd":"4186","indian_port":"BOMBAY AIR","hs_no":"29339100","bill_no":"7371058","productDescription":"API","marketType":"REGULATED MARKET","country":"ITALY","selfForZScoreResived":"Pharma Grade","supplierPort":"NA","supplierAddress":"","customerAddress":"304,ATLANTA ARCADE, MAROL CHURCH RD,ANDHERI EAST Contac"}]
    22-Feb-2021
    05-Feb-2022
    KGS
    overview
    Loading...

    Average Price (USD/KGS)

    Number of Transactions

    Total Quantity (KGS)

    Total Value (USD)

    Quantity (KGS) & Unit rate (USD/KGS) over time

    API Imports and Exports

    Importing Country Total Quantity
    (KGS)    		 Average Price
    (USD/KGS)    		 Number of Transactions

    Upgrade, download data, analyse, strategize, subscribe with us contact

    DRUG PRODUCT COMPOSITIONS

    Do you need Business Intel? Ask us

    DOSAGE - TABLET;ORAL - 11.25MG **Federal Regi...DOSAGE - TABLET;ORAL - 11.25MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

    USFDA APPLICATION NUMBER - 17105

    read-more

    DOSAGE - CAPSULE;ORAL - 15MG **Federal Regist...DOSAGE - CAPSULE;ORAL - 15MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

    USFDA APPLICATION NUMBER - 17105

    read-more

    DOSAGE - TABLET;ORAL - 22.5MG **Federal Regis...DOSAGE - TABLET;ORAL - 22.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

    USFDA APPLICATION NUMBER - 17105

    read-more

    DOSAGE - CAPSULE;ORAL - 3.75MG **Federal Regi...DOSAGE - CAPSULE;ORAL - 3.75MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

    USFDA APPLICATION NUMBER - 17105

    read-more

    DOSAGE - CAPSULE;ORAL - 7.5MG **Federal Regis...DOSAGE - CAPSULE;ORAL - 7.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

    USFDA APPLICATION NUMBER - 17105

    read-more

    Related Excipient Companies

    Upload your portfolio for free, ask us

    Excipients by Applications

    Click here to find the perfect excipient manufacturers by their capabilities

    Fillers, Diluents & Binders

    read-more
    read-more

    Lubricants & Glidants

    read-more
    read-more

    Direct Compression

    read-more
    read-more

    Disintegrants & Superdisintegrants

    read-more
    read-more

    Thickeners and Stabilizers

    read-more
    read-more

    Granulation

    read-more
    read-more

    Co-Processed Excipients

    read-more
    read-more

    Controlled & Modified Release

    read-more
    read-more

    Coating Systems & Additives

    read-more
    read-more

    Parenteral

    read-more
    read-more

    Taste Masking

    read-more
    read-more

    Emulsifying Agents

    read-more
    read-more

    Chewable & Orodispersible Aids

    read-more
    read-more

    Film Formers & Plasticizers

    read-more
    read-more

    API Stability Enhancers

    read-more
    read-more

    Rheology Modifiers

    read-more
    read-more

    Topical

    read-more
    read-more

    Surfactant & Foaming Agents

    read-more
    read-more

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more

    Global Sales Information

    Do you need Business Intel? Ask us

    Market Place

    Do you need sourcing support? Ask us

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    USP

    read-more
    read-more

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search